Drug interactions
Cyclophosphamide + Ublituximab
Severity: Moderate
Cyclophosphamide and Ublituximab: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Both drugs are immunosuppressive, with ublituximab depleting B cells and cyclophosphamide suppressing lymphocytes and bone marrow. Together they raise the risk of infection, including serious or opportunistic infections. Effects may last well beyond the dosing period.
What this interaction means in plain words
Cyclophosphamide and Ublituximab can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Cyclophosphamide belongs to Oncology; Ublituximab belongs to Miscellaneous.
Why it happens
Additive immunosuppression through B-cell depletion and cytotoxic lymphocyte suppression.
What to do
Screen for hepatitis B and other infections before use and monitor for infection during therapy. Avoid live vaccines and consider antimicrobial prophylaxis as indicated.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Cyclophosphamide and Ublituximab, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Cyclophosphamide
Other interactions of Ublituximab
Frequently asked questions
Can I take Cyclophosphamide with Ublituximab?
MediHelp rates the interaction as moderate. Cyclophosphamide and Ublituximab can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Both drugs are immunosuppressive, with ublituximab depleting B cells and cyclophosphamide suppressing lymphocytes and bone marrow. Together they raise the risk of infection, including serious or opportunistic infections. Effects may last well beyond the dosing period.
How serious is the interaction between Cyclophosphamide and Ublituximab?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Screen for hepatitis B and other infections before use and monitor for infection during therapy. Avoid live vaccines and consider antimicrobial prophylaxis as indicated.
What other medicines interact with Cyclophosphamide?
MediHelp also lists interactions of Cyclophosphamide with, for example, Adenovirus types 4 and 7 live, Belatacept, Bendamustine. The full list is on the Cyclophosphamide page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
